MDGL
MADRIGAL PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$447.09
−0.59%Year over year
Reported trailing growth
- Revenue
- +149.0%
- EBITDA
- -9.5%
- EBIT
- -4.1%
- EPS
- -0.3%
- Free cash flow
- +33.1%
- Operating cash flow
- +35.7%
Forward estimates
Based on analyst estimates
- Revenue
- +52.7%
- EBITDA
- +136.8%
- EPS
- +114.6%
Three-year CAGR
- Revenue
- +432.1%
- EBITDA
- +41.2%
- EBIT
- +39.7%
- Net income
- +38.1%
- EPS
- +41.3%
- Free cash flow
- +58.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026